Ultra low dose interleukin-2 therapy promotes a type I cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies

Journal of Clinical Investigation

Volumn 101, Issue 6, 1998, Pages 1373-1378

  Khatri, Vijay P ^a   Fehniger, Todd A ^a,b,c   Baiocchi, Robert A ^a,b,c   Yu, Feng ^a   Shah, Manisha H ^a,b,c   Schiller, Daryl S ^a   Gould, Margaret ^a   Gazzinelli, Ricardo T ^d   Bernstein, Zale P ^a   Caligiuri, Michael A ^a,b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

AIDS; Immunotherapy; Interferon ; Interleukin 2; Natural immunity

Indexed keywords

CYTOKINE; DELAVIRDINE; DIDANOSINE; GAMMA INTERFERON; INTERLEUKIN 2; LAMIVUDINE; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0032520908     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI2038     Document Type: Article

References (33)

1. Clerici, M., and G.M. Shearer. 1994. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today. 15:575-581.
2. Kinter. A., and A.S. Fauci. 1996. Interleukin-2 und human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement, Immunol. Res. 15:1-15.
3. Chehimi. J., S.E. Starr. I. Frank, A. D'Andrea, X. Ma, R.R. MacGregor, J. Sennelier, and G. Trinehieri. 1994. Impaired interlcukin 12 production in human immunodeficiency virus-infected patients. J. Exp. Med. 179:1361-1366.
4. Maggi, E., M. Mazzetti, A. Ravina, F. Annunziato, M. de Carli, M.P Piccinni, R. Manetti, M. Carbonari, A.M. Pesce, G. del Prete, and S. Romagnani. 1944. Ability of HIV to promote a TH1 to THO shift and to replicate preferentially in TH2 and TH0 cells. Science. 265:244-248.
5. Jouanguy, E., F. Altare, S. Lamhamedi, P. Revy, J.F. Emile, M. Newport, M. Levin, S. Blanche, E. Sehoun, A. Fischer, and J.L. Casanova. 1996. Interferon-gamma-rcceptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335:1956-1961.
6. Newport, M.J., C.M. Huxley, S. Huston, C.M. Hawrylowicz, B.A. Oostra, R. Williamson, and M. Levin. 1996. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobactcrial infection. N. Engl. J. Med. 335:1941-1949.
7. Bancroft, G.J. 1993. The role of natural killer cells in innate resistance to infection. Curr. Opin. Immunol. 5:503-510.
8. Gazzinelii, R.T., S. Hieny, T.A. Wynn, S. Wolf, and A. Sher. 1993. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc. Natl. Acad. Sci. USA. 90:6115-6119.
9. bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur. J. Immunol. 27:354-360.
10. Tripp, C.S., S.F. Wolf, and E.R. Unanue. 1993. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc. Natl. Acad. Sci. USA. 90:3725-3729.
11. Fauci, A.S. 1993. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science. 262:1011-1018.
12. Caligiuri, M.A. 1993. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin. Oncol. 20:3-10.
13. Jacobson, E.L., F. Pilaro, and K.A. Smith. 1996. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. USA. 93:10405-10410.
14. Bernstein, Z.P., M.M. Porter, M. Gould, B. Lipman. E.M. Bluman, C.C. Stewart, R.G. Hewitt, G. Fyfe, B. Poicsz, and M.A. Caligiuri. 1995. Prolonged administration of low-dose imerleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical loxicity. Blood. 86:3287-3294.
15. Bernstein, Z.P., G. Barresi, M. Gould, S. Jacobs, B. Poiesz, and M.A. Caligiuri. 1997. A phase II study of daily subcutaneous (SQ) low dose interleukin-2 (IL-2) in HIV-associated malignancies. J. Acquired Immune Deflc. Syndr. Hum. Retrovrol. 14:A40. (Abstr.)
16. Stewart, C.C., and S.J. Stewart. 1994. Cell preparation for the identificalion of leukocytes. Methods Cell Biol. 41:39-60.
17. Reiner, S.L., S. Zheng, D.B. Corry, and R.M. Locksley. 1993. Constructing polycompetitor cDNAs for the quantitative PCR methods. J. Immunol. Methods. 165:37-16.
18. Ross, M.B., and M.A. Caligiuri. 1997. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood. 89:910-918.
19. Gong, J.H., G. Maki, and H.G. Klingemann. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia (Bushigstoke). 8:652-658.
20. Gazzinelli, R.T., S. Bala, R. Stevens, M. Baseler, L. Wahl, J. Kovacs, and A. Sher. 1995. HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasiteinduced monokines. J. Immunol. 155:1565-1574.
21. Graziosi, C. G. Pantaleo, K.R. Gantt, J.P. Fortin, J.F. Demarest, O.J. Cohen, R.P. Sckaly, and A.S. Fauci. 1994. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science. 265:248-252.
22. Romagnani, S. 1995. Biology of human TH1 and TH2 cells. J. Clin. Immunol. 15:121-129.
23. Mosmann, T.R., and S. Sad. 1996. The expanding universe ol T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:138-146.
24. Wu. C., R.R. Warrier, X. Wang, D.H. Presky, and M.K. Gately. 1997. Regulation of interleukin-12 receptor betal chain expression and interleukin-12 binding by human peripheral blood mononuclear cells. Eur. J. Immunol. 27:147-154.
25. Kubin, M., J.M. Chow, and G. Trinchieri. 1994. Differential regulation of interleukin-12 (IL-12), tumor necrosis factor alpha, and IL-I beta production in human myeloid leukemia cell lines and peripheral blood mononuclear cells. Blood. 83:1847-1855.
26. Ma, X., J.M. Chow, G. Gri, G. Carra, F. Gerosa, S.F. Wolf, R. Dzialo, and G. Trinchieri. 1996. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med. 183:147-157.
27. Chomarat, P., M.C. Rissoan, J. Banchereau, and P. Miossec. 1993. Interferon gamma inhibits interleukin 10 production by monocytes. J. Exp. Med. 177:523-527.
28. Denkers, E.Y., R.T. Gazzinelii, D. Martin, and A. Sher. 1993. Emergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice. J. Exp. Med. 178:1465-1472.
29. Soudeyns, H., N. Rebai, G.P. Pantaleo, C. Ciurli, T. Boghossian, R.P. Sekaly, and A.S. Fauci. 1993. The T cell receptor V beta repertoire in HIV-I infection and disease. Semin. Immunol. 5:175-185.
30. Connors, M., J.A. Kovacs, S. Krevat, J.C. Gea-Banacloche, M.C. Sneller, M. Flanigan, J.A. Metcalf, R.E. Walker, J. Falloon, M. Baseler, et al. 1997. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat. Med. 3:533-540.
31. Schnittman, S.M., and A.S. Fauci. 1994. Human immunodeficiency virus and acquired immunodeficiency syndrome: an update. Adv. Int. Med. 39:305-355.
32. Meyaard, L., S.A. Otto, R.R. Jonker. M.J. Mijnster, R.P. Keet, and F. Miedema. 1992. Programmed death of T cells in HIV-1 infection. Science. 257: 217-219.
33. Murray, H.W. 1994. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am. J. Med. 97:459-467.